


AMENDMENTS TO THE CLAIMS


This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:


1. (currently amended): A uracil derivative represented by the general formula (I):



wherein X represents a group selected from NHCO, NHCH₂, CO, CONH and CH₂NH; R¹ represents a hydrogen atom or a substituted or unsubstituted alkyl group of 1 to 6 carbon atoms; R² represents the general formula (II) or (III):



(II)



(III)

wherein m is 0 or 1, n is an integer of 1 to 3, Y is OH or NH₂, and each dotted line indicates a bonding position, provided that when R² represents the general formula (III), X represents NHCO or NHCH₂; R³ and R⁴ independently represent a hydrogen atom or an alkyl group of 1 to 6 carbon atoms; and Ar represents a phenyl group substituted by alkyl groups of 1 to 6 carbon

atoms at the o- and m-positions, a substituted or substituted-unsubstituted heteroaryl group or a bicyclic aromatic group,
or a pharmaceutically acceptable salt thereof.

2. (original): A uracil derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein R² represents the general formula (II) in the general formula (I).

3. (original): A uracil derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein R² represents the general formula (III) in the general formula (I).

4. (previously presented): A uracil derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein Ar represents a phenyl group substituted by alkyl groups of 1 to 6 carbon atoms at the o- and m-positions in the general formula (I).

5. (previously presented): A uracil derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein Ar represents a substituted or unsubstituted heteroaryl group in the general formula (I).

6. (previously presented): A uracil derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein Ar represents a bicyclic aromatic group in the general formula (I).

7. (previously presented): A uracil derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein X represents NHCO in the general formula (I).

8. (previously presented): A pharmaceutical composition for the treatment of allergic diseases comprising a uracil derivative or a pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

9. (previously presented): A pharmaceutical composition for the treatment of pruritus comprising a uracil derivative or a pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

10. (previously presented): A uracil derivative or a pharmaceutically acceptable salt thereof according to claim 2, wherein Ar represents a phenyl group substituted by alkyl groups of 1 to 6 carbon atoms at the o- and m-positions in the general formula (I).

11. (previously presented): A uracil derivative or a pharmaceutically acceptable salt thereof according to claim 2, wherein Ar represents a substituted or unsubstituted heteroaryl group in the general formula (I).

12. (previously presented): A uracil derivative or a pharmaceutically acceptable salt thereof according to claim 2, wherein Ar represents a bicyclic aromatic group in the general formula (I).